Clinical strategies for Biosimilars development

Clinical strategies for Biosimilars development Photo

Biosimilars are surmounting pharmaceutical business division from latest three decades and arrangements seem to expand intelligently. Advances in the biotechnology incite to change and presentation of new natural things (Biosimilars) to treat various life-debilitating sicknesses. Biosimilars are natural solutions that are passed on after the expiry of the patent of certified pioneer and incorporate Hatch-Waxman act is the correction to Federal, Food, Drug and Cosmetics Act which built up the cutting edge arrangement of approval of generics through Abbreviated New Drug Applications.

  • Biosimilar development challenges
  • Advances in Biosimilar production and Technologies
  • Legal Considerations for Biosimilars
  • Biosimilar Uptake and Market Considerations

Are you interested in

Mail us at

Programs & Speaking Engagement
Group Discounts and Delegates
More details about

Authorization Policy

By registering for the conference you grant permission to Allied Academies to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute,broadcast,edit and/or digitize the resulting images and materials in publications, advertising materials,or in any other form worldwide without compensation. Taking of photographs and/or video taping during any session is prohibited. Contact us for any queries
Copyright © 2017-2018 Allied Academies, All Rights Reserved.